Weeks after the Food and Drug Administration said opioid painkiller Opana ER should be removed from the market amid concerns about the potential for abuse, Endo Pharmaceuticals has agreed to pull the drug, which has been linked to serious outbreaks of HIV and hepatitis C. [More]
endo pharmaceuticals
Endo Pharmaceuticals Agrees To Remove Opioid Painkiller Linked To HIV Outbreak From The Market
By 7.7.17
FDA Requests Opioid Painkiller Be Removed From The Market, Citing Abuse Risks, HIV Outbreak
By 6.8.17
The Food and Drug Administration has asked Endo Pharmaceuticals, the manufacturer of Opana ER, an extended-release semi-synthetic opioid painkiller, to remove the drug from the market, after the agency concluded that the drug’s potential for abuse outweighed its therapeutic value. [More]
Feds Say Drug Company Illegally Blocked Lower-Cost Generics From Entering Market
By 3.31.16
When a drug patent nears its end, drug companies sometimes do really stupid, potentially illegal things to delay or prevent their bottom line being dinged by a lower-cost generic version. One drug company is accused of not just paying off a generic drug maker to delay the release of its version of two medications, but further hurting consumers by agreeing to not compete with the generic. [More]
Some Endocet Recalled For Having Double The Acetaminophen
By 6.28.11
Bottles of the pain-killing drug Endocet are being recalled because they erroneously contain 650 mg of acetaminophen while their label says 325 mg. While no injuries have been reported, consuming more acetaminophen than prescribed can lead to liver toxicity. [More]
